In brief
- Translational Psychiatry, part of the Nature portfolio, publishes the first study comparing the epigenetic footprint of ketamine and MDMA.
- Ketamine modified 1,210 methylation sites and MDMA 2,074; almost all were distinct, except for two overlapping genes, PTPRN2 and SHANK2, which are related to neuronal plasticity.
- The study involved 36 people in total, and several authors declared financial ties to organizations and companies in the sector.
DNA methylation is a chemical marker placed on genetic material without altering its sequence. It acts like a switch, activating or silencing genes based on what happens in the body. A team from Arizona State University, the University of Southern California, and the genetic analysis company TruDiagnostic examined what happens to these switches in people who have received ketamine or MDMA in a clinical setting.
How it was measured
The researchers took blood samples from 20 people treated with ketamine and saliva samples from 16 participants in an MDMA trial, both before and after treatment, to compare which positions in the genome had changed state. This is known in technical jargon as an epigenome-wide association study—in plain English, a scan to see where changes occurred.
Different paths, two points in common
Ketamine altered methylation at 1,210 positions, associated with 405 genes and 169 functional networks. MDMA affected 2,074 positions, linked to 346 genes and 183 networks. The lists barely overlap, and in several cases, the direction of the change was opposite between one substance and the other. However, two genes appeared in both: PTPRN2 and SHANK2, both involved in communication between neurons and synaptic plasticity—the very terrain where research has been situating the rapid antidepressant effect of these compounds. The analysis also pointed to genes linked to immune regulation, a line of inquiry that has been gaining weight in psychiatry for several years.
What it implies
Size matters: 36 people in total. The samples are from blood and saliva, not brain tissue, which cannot be accessed in vivo; therefore, extrapolating to what happens in neurons is an inference, not a direct measurement. The study also does not measure whether these changes translate into clinical improvement or how long they last. The authors themselves describe it as a first snapshot. Furthermore, there are declared conflicts of interest in the article that should be kept in mind: the research was funded by two non-profit organizations that promote this field, one of the authors received payment from MAPS or Lykos Therapeutics while working on the trial from which the MDMA samples were taken, and two other authors are employees of the company that performed the genetic analyses. None of this invalidates the data, but it is part of what must be known to weigh them. Even so, the work opens an interesting path: if these substances leave a measurable epigenetic mark in the blood, perhaps one day it will be possible to track their effect without relying solely on questionnaires.
Source
- Semple, M. G., Mennenga, S. E., Smith, R. et al. Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA. Translational Psychiatry, July 11, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
